Shares of Viggle Inc. (NASDAQ:VGGL) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 1,346,340 shares, a growth of 48.8% from the November 28th total of 904,661 shares, Analyst Ratings.Net reports. Viggle Inc. (NASDAQ:VGGL) in last trading activity moved up 25.38% to close at $3.31. Company weekly performance is 14.53% while its quarterly performance stands at 2.48%. Viggle Inc. (NASDAQ:VGGL) is -93.63% away from its 52 week high.
On December 19, 2014, Walter Energy, Inc. (NYSE:WLT) entered into award agreements (each, an “Award Agreement”) with three of the Company’s current named executive officers, Walter J. Scheller, III, William G. Harvey and Earl H. Doppelt. The terms of the Award Agreements with such executive officers provide that they will receive a cash award (the “Award”), to be paid by the Company on the effective date of the Award Agreement, equal to a multiple of such executive officer’s current annual base salary. On last trading day Walter Energy, Inc. (NYSE:WLT) moved up 5.07% to close at $1.45. Its volatility for the week is 9.11% while volatility for the month is 11.93%. WLT’s sales growth for past 5 years was 10.10% and its EPS growth for past 5 years was -27.40%. Walter Energy, Inc. (NYSE:WLT) monthly performance is -23.68%.
Paragon Offshore plc (NYSE:PGN) repurchased an aggregate principal amount of $25.2 million of its senior unsecured notes in December 2014 at an aggregate cost of $15.3 million including accrued interest. The repurchases consisted of $15.2 million of its 6.75 percent senior notes due 2022 and $10.0 million of its 7.25 percent senior notes due 2024.Paragon Offshore plc (NYSE:PGN) has 1.90% insider ownership while its institutional ownership stands at 58.50%. In last trading activity company’s stock closed at $3.17.
Equities researchers at Roth Capital lifted their target price on shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from $1.30 to $2.30 in a research report issued on Tuesday. The firm currently has a “neutral” rating on the stock. Roth Capital’s target price would suggest a potential downside of 0.43% from the company’s current price. On Friday shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) closed at $2.75. Company’s sales growth for last 5 years was 8.20%.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) on 6 December announced new preliminary data from the Phase 2 component of an ongoing Company-sponsored Phase 1/2 trial of TH-302, the Company’s lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib (Velcade®) and low-dose dexamethasone (“TBorD”) for the treatment of patients with relapsed/refractory multiple myeloma (MM). The median number of prior therapies was 8 (range, 4-12). On last trading day Threshold Pharmaceuticals Inc. (NASDAQ:THLD) moved up 7.86% to close at $3.43. Its volatility for the week is 4.97% while volatility for the month is 5.31%. THLD’s sales growth for past 5 years was 54.90% and its EPS growth for past 5 years was 24.30%. Threshold Pharmaceuticals Inc. (NASDAQ:THLD) monthly performance is 16.67%.